MedTrace Logo

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

NCT05339386 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2026-05-01

No results posted yet for this study

Summary

In this study, hyperpolarized 129Xe MRI will be used to evaluate treatment efficacy in patients with pulmonary arterial hypertension (PAH). Participants will be imaged at 4 timepoints (baseline, 6 weeks post-therapy initiation, 12 weeks, and 18 weeks). Images will be analyzed to develop new biomarkers and to understand treatment effects.

Conditions

Interventions

DRUG

Hyperpolarized Xe129

Lung MRI using gaseous contrast agent hyperpolarized 129Xe.

Sponsors & Collaborators

Principal Investigators

  • Peter Niedbalski, PHD · University of Kansas Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2025-03-31
Completion
2025-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05339386 on ClinicalTrials.gov